The role of Toll-like receptors in non-infectious lung injury

Cell Research

Volumn 16, Issue 8, 2006, Pages 693-701

  Jiang, Dianhua ^a   Liang, Jiurong ^a   Li, Yuhang ^b   Noble, Paul W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Hyaluronan; Inflammation; Lung injury; Toll like receptors

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; ISOPROTEIN; LIGAND; TOLL LIKE RECEPTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; EPITHELIUM CELL; GENETICS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD44; EPITHELIAL CELLS; HUMANS; HYALURONIC ACID; IMMUNITY, NATURAL; LIGANDS; MACROPHAGES; PROTEIN ISOFORMS; RESPIRATORY DISTRESS SYNDROME, ADULT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 33747483267     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7310085     Document Type: Review

References (99)

1. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-787.
2. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003; 15:396-401.
3. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54(Part 1):1-13.
4. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-397.
5. Lauw FN, Caffrey DR, Golenbock DT. Of mice and man: TLR11 (finally) finds profilin. Trends Immunol 2005; 26:509-511.
6. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-995.
7. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
8. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11:443-451.
9. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-376.
10. Frantz S, Kobzik L, Kim YD, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104:271-280.
11. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11:1173-1179.
12. Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M. Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998; 188:2091-2097.
13. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998; 395:284-288.
14. Underhill DM, Ozinsky A, Hajjar AM, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999; 401:811-815.
15. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-2088.
16. Bochkov VN, Kadl A, Huber J, et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002; 419:77-81.
17. Doyle S, Vaidya S, O'Connell R, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002; 17:251-263.
18. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
19. Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10:1366-1373.
20. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-1531.
21. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745.
22. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Molecular Cell 1998; 2:253-258.
23. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9:143-150.
24. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278:1612-1615.
25. Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci USA 1997; 94:12829-12832.
26. Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 1996; 271:1128-1131.
27. Ye H, Arron JR, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002; 418:443-447.
28. Shibuya H, Yamaguchi K, Shirakabe K, et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996; 272:1179-1182.
29. Takaesu G, Kishida S, Hiyama A, et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 2000; 5:649-658.
30. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, et al. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999; 398:252-256.
31. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420:329-333.
32. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78-83.
33. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640-643.
34. Yamamoto M, Sato S, Hemmi H, et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003; 4:1144-1150.
35. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164:558-561.
36. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, et al. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol 2005; 175:3594-3602.
37. Vabulas RM, Ahmad-Nejad P, da Costa C, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276:31332-31339.
38. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279:7370-7377.
39. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298:1025-1029.
40. Guillot L, Balloy V, McCormack FX, et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168:5989-5992.
41. Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202:1131-1139.
42. Taylor KR, Trowbridge JM, Rudisill JA, et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279:17079-17084.
43. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99-111.
44. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168:5233-5239.
45. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukocyte Biol 2004.
46. Hirschfeld M, Ma Y, Weis JH, et al. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165:618-622.
47. Gao B, Tsan MF. Recombinant human heat shock protein 60 does not induce the release of tumor necrosis factor alpha from murine macrophages. J Biol Chem 2003; 278:22523-22529.
48. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem 2003; 278:174-179.
49. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277:15107-15112.
50. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277:15028-15034.
51. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-2233.
52. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-3752.
53. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 2001; 276:5197-5203.
54. Berdeli A, Celik HA, Ozyurek R, et al. TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med 2005; 83:535-541.
55. Hamann L, Gomma A, Schroder NW, et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med 2005; 83:478-485.
56. Cooke GS, Segal S, Hill AV. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:1978-1980; author reply 1978-1980.
57. Sabroe I, Whyte MK, Wilson AG, et al. Toll-like receptor (TLR) 4 polymorphisms and COPD. Thorax 2004; 59:81.
58. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10:416-421.
59. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-192.
60. Inoue K, Takano H, Yanagisawa R, et al. The role of toll-like receptor 4 in airway inflammation induced by diesel exhaust particles. Arch Toxicol 2006; 80:275-279.
61. Kleeberger SR, Reddy S, Zhang LY, Jedlicka AE. Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. Am J Respir Cell Mol Biol 2000; 22:620-627.
62. Hayashi T, Beck L, Rossetto C, et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004; 114:270-279.
63. Karimi K, Sarir H, Mortaz E, et al. Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir Res 2006; 7:66.
64. Pons J, Sauleda J, Regueiro V, et al. Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir Res 2006; 7:64.
65. Droemann D, Goldmann T, Tiedje T, et al. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005; 6:68.
66. Barsness KA, Arcaroli J, Harken AH, et al. Hemorrhage-induced acute lung injury is TLR-4 dependent. Am J Physiol Regul Integr Comp Physiol 2004; 287:R592-599.
67. Fan J, Li Y, Vodovotz Y, et al. Hemorrhagic shock-activated neutrophils augment TLR4 signaling-induced TLR2 upregulation in alveolar macrophages: role in hemorrhage-primed lung inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290: L738-L746.
68. Zhang X, Shan P, Qureshi S, et al. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol 2005; 175:4834-4838.
69. Laurent TC 1988. The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives. Portland Press, London.
70. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997; 242:27-33.
71. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296:155-158.
72. Heine H, Rietschel ET, Ulmer AJ. The biology of endotoxin. Mol Biotechnol 2001; 19:279-296.
73. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985; 228:1324-1326.
74. West DC, Kumar S. Hyaluronan and angiogenesis. Ciba Found Symp 1989; 143:187-201; discussion 201-187, 281-185.
75. Horton MR, Burdick MD, Strieter RM, et al. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN-gamma in mouse macrophages. J Immunol 1998; 160:3023-3030.
76. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996; 98:2403-2413.
77. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 1996; 183:2373-2378.
78. Ohkawara Y, Tamura G, Iwasaki T, et al. Activation and transforming growth factor-beta production in eosinophils by hyaluronan. Am J Respir Cell Mol Biol 2000; 23:444-451.
79. Fitzgerald KA, Bowie AG, Skeffington BS, O'Neill LA. Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells. Journal of Immunology 2000; 164:2053-2063.
80. Oliferenko S, Kaverina I, Small JV, Huber LA. Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia outgrowth [published erratum appears in J Cell Biol 2000 Apr 3;149(1):following 236]. Journal of Cell Biology 2000; 148:1159-1164.
81. Termeer CC, Hennies J, Voith U, et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. Journal of Immunology 2000; 165:1863-1870.
82. Aruffo A, Stamenkovic I, Melnick M, et al. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61:1303-1313.
83. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4:33-45.
84. Cichy J, Pure E. The liberation of CD44. J Cell Biol 2003; 161:839-843.
85. Mummert ME, Mohamadzadeh M, Mummert DI, et al. Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J Exp Med 2000; 192:769-779.
86. Jameson JM, Cauvi G, Sharp LL, et al. gammadelta T cell-induced hyaluronan production by epithelial cells regulates inflammation. J Exp Med 2005; 201:1269-1279.
87. Schmits R, Filmus J, Gerwin N, et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 1997; 90:2217-2233.
88. Hodge-Dufour J, Noble PW, Horton MR, et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. Journal of Immunology 1997; 159:2492-2500.
89. Khaldoyanidi S, Moll J, Karakhanova S, et al. Hyaluronate-enhanced hematopoiesis: two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages. Blood 1999; 94:940-949.
90. Yang RB, Mark MR, Gurney AL, Godowski PJ. Signaling events induced by lipopolysaccharide-activated toll-like receptor 2. Journal of Immunology 1999; 163:639-643.
91. Mummert ME, Mummert D, Edelbaum D, et al. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J Immunol 2002; 169:4322-4331.
92. Beck-Schimmer B, Oertli B, Pasch T, Wuthrich RP. Hyaluronan induces monocyte chemoattractant protein-1 expression in renal tubular epithelial cells. J Am Soc Nephrol 1998; 9:2283-2290.
93. Oertli B, Beck-Schimmer B, Fan X, Wuthrich RP. Mechanisms of hyaluronan-induced up-regulation of ICAM-1 and VCAM-1 expression by murine kidney tubular epithelial cells: hyaluronan triggers cell adhesion molecule expression through a mechanism involving activation of nuclear factor-kappa B and activating protein-1. J Immunol 1998; 161:3431-3437.
94. Ito T, Williams JD, Al-Assaf S, et al. Hyaluronan and proximal tubular cell migration. Kidney Int 2004; 65:823-833.
95. Mascarenhas MM, Day RM, Ochoa CD, et al. Low molecular weight hyaluronan from stretched lung enhances interleukin-8 expression. Am J Respir Cell Mol Biol 2004; 30:51-60.
96. Lawrence T, Bebien M, Liu GY, et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005; 434:1138-1143.
97. Chen LW, Egan L, Li ZW, et al. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003; 9:575-581.
98. O'Neill LA. TLRs play good cop, bad cop in the lung. Nat Med 2005; 11:1161-1162.
99. Sha Q, Truong-Tran AQ, Plitt JR, et al. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004; 31:358-364.